Xenetic Biosciences Inc. (XBIO)
NASDAQ: XBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.28M
- EPS (TTM)
- -$1.55
- Dividend yield
- None
- 52-week range
- 1.25 – 4.94
- Day range
- 1.25 – 1.56
- Volume / Avg
- 21.76K / 73.30K
- Beta
- —
- Shares outstanding
- 2.34M
52-week range
XBIO stock today
Xenetic Biosciences (XBIO) closed at $1.40 on Nov 20, down 9.09% (-$0.14), versus the S&P 500's 3.70% decline. Trading was light, with 21.76K shares changing hands, about 30% of the average daily volume. At this level, XBIO sits near the bottom of its 52-week range of $1.25 to $4.94: 71.7% below the high and 12.0% above the low.
Xenetic Biosciences has posted a net loss over the last twelve months (EPS of -$1.55), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Xenetic Biosciences
Company profileXenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. James F. Parslow
- Headquarters
- Framingham, MA
- Employees
- 2
- Website
- xeneticbio.com
Financial highlights
Full financialsIn fiscal 2025, Xenetic Biosciences generated $3.0 million in revenue, up 19.0% from fiscal 2024. Xenetic Biosciences reported a net loss of $2.7 million, compared with a loss of $4.0 million a year earlier. Operating margin was -95.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.98M | $2.50M | $2.54M | $1.71M | $1.16M |
| Growth | +19.04% | -1.56% | +48.80% | +47.06% | +165.64% |
| Net income | $-2.68M | $-3.96M | $-4.13M | $-6.55M | $-5.65M |
| EPS (diluted) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.72 vs —
Xenetic Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APREAprea Therapeutics Inc. | 0.229 | -53.56% | $3.25M | vs XBIO |
| XTLBXTL Biopharmaceuticals Ltd. ADR | 1.37 | -5.84% | $3.37M | vs XBIO |
| NRSNNeuroSense Therapeutics Ltd. | 1.28 | +1.59% | $3.19M | vs XBIO |
| KPRXKiora Pharmaceuticals Inc. | 0.7202 | -12.28% | $3.19M | vs XBIO |
| MDCXMedicus Pharma Ltd. | 1.14 | -2.16% | $3.16M | vs XBIO |
| AZTRAzitra Inc | 0.5168 | -2.75% | $3.13M | vs XBIO |
| GELSGelteq Limited | 0.2701 | -3.74% | $3.11M | vs XBIO |
| SKYESkye Bioscience Inc. | 0.70 | -11.03% | $3.10M | vs XBIO |
Indexes, lists and sector
Xenetic Biosciences stock FAQ
What is Xenetic Biosciences's stock price today?
XBIO last traded at $1.40 as of Nov 20, 4:00 PM EST, down 9.09% on the day. Prices are delayed at least 15 minutes.
Who is Xenetic Biosciences's CEO?
Mr. James F. Parslow is the chief executive officer of Xenetic Biosciences Inc., which has about 2 employees.
What is the XBIO 52-week high?
The 52-week high for XBIO is $4.94 and the 52-week low is $1.25. The stock is currently 71.7% below its high.